FilingReader Intelligence
Shyndec Pharma revamps governance: Board changes, articles amended
June 11, 2025 at 11:38 PM UTC•By FilingReader AI
Shanghai Shyndec Pharmaceutical [SSE:600420] is undertaking a significant overhaul of its corporate governance structure, according to a new filing. The company will eliminate its board of supervisors, transferring its duties to the audit and risk management committee under the board of directors. Additionally, the board will now include one employee representative. These changes will be put to shareholders for approval.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
SSE:600420•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Shyndec Pharmaceutical publishes news
Free account required • Unsubscribe anytime